AD Pipeline Update: Leo’s IL-22RA1 Blocker Shows Promise in Phase 2a MoA Trial
Temtokibart, LEO Pharma’s investigational interleukin 22 receptor alpha 1 (IL-22RA1) inhibitor, induces molecular responses related to atopic dermatitis (AD) as early as Week 1, finds a Phase 2a Mechanism of Action (MoA) trial presented at the European Academy of Dermatology & Venereology (EADV) 2024 meeting in Amsterdam. The study assessed the mechanistic impact of investigational […]